Drug Profile
Cytomegalovirus-specific T cells - AlloVir
Alternative Names: CMV-specific T cell therapy - AlloVir; CMV-specific T cells - AlloVir; Cytomegalovirus-specific T cell therapy - AlloVir; HLA-matched Viralym-C cells; Human leukocyte antigen (HLA)-matched CMV-specific T lymphocytes - AlloVir; Viralym-CLatest Information Update: 19 Jul 2019
Price :
$50
*
At a glance
- Originator ViraCyte
- Developer AlloVir
- Class T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cytomegalovirus infections
Most Recent Events
- 22 May 2019 ViraCyte is now called AlloVir
- 28 Oct 2018 No recent reports of development identified for phase-I development in Cytomegalovirus infections(In adolescents, In children, In adults) in USA (IV, Infusion)
- 11 Jul 2017 Updated efficacy data from a phase I trial in Cytomegalovirus infections released by ViraCyte